Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The new centre brings advanced corneal procedures pioneered in India
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The FDA aims to make a decision by April 8, 2026
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Subscribe To Our Newsletter & Stay Updated
